Sponsorsview all sponsors
MSHO continuously contacts legislators, provides comments to policy makers and collaborates with payers on issues of concern to those delivering care to cancer patients.
It is important that our members are aware of meetings, web casts, and other educational opportunities specifically designed to address the complexities of cancer care.
XOFIGO (radium Ra 223 dichloride) Approved for New Treatment
The FDA approves Xofigo (radium Ra 223 dichloride) Injection as a NEW treatment for castration-resistant prostate cancer with bone metastases READ MORE